IntelliCell BioSciences, Inc. Announces It Will Open Adipose Tissue Processing Center in Orlando

IntelliCell BioSciences, Inc. Announces It Will Open Adipose Tissue Processing Center in Orlando

NEW YORK, NY–(Aug 3, 2011 11:11 AM) – IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) (“IntelliCell” or the “Company”), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today it has signed an agreement to open an Adipose Stem Cell Processing Center in Orlando, Florida in the next six weeks. This center will make adipose derived stem cells available for doctors in the metro Orlando area.

The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the US FDA published its laws on autologous stem cells the field has expanded rapidly. Currently, numerous doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.

“We believe IntelliCell is setting the gold standard for adipose stem cell processing. Our technology provides stem cell counts and viability checks for each specimen processed, as well as documents the quality and quantity of the stem cells produced. The Company’s entry into the Orlando market will grant us the opportunity to offer this community of physicians, researchers, and healthcare centers access to, what we believe to be, the highest number and quality stromal vascular fraction (SVF) cells which contain adult stem cells through our proprietary, FDA compliant process. We are very pleased to see Orlando receive this promising service,” stated IntelliCell Chairman and CEO, Dr. Steven Victor.

IntelliCell’s adipose stem cell processing technique takes approximately 30 minutes and the stem cells can be returned to the doctor in the same day. Autologous adipose stem cells are on the cutting edge of medicine and IntelliCell is excited to be one of the companies to participate in this field.

IntelliCell has developed an in-house technology where it can easily process stromal vascular cells containing a high concentration of adipose stem cells with excellent viability. At present, management believes it is the only company that does not use enzymes in processing adipose tissue and actually counts and checks the adipose stem cells they manufacture.

About IntelliCell Biosciences, Inc.

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on setting up tissue processing centers throughout the United States with managing partners. The centers will receive and employ the IntelliCell™ process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells™ to the physicians the same day labeled “autologous homologous.” IntelliCell has already established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach. In the future, IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit https://www.intellicellbiosciences.com or call 212 1329875.

Forward-Looking Statements

Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.